Molecular characterization of carbapenem-resistant

Acinetobacter species in an Irish university hospital:

predominance of Acinetobacter genomic species 3 by Boo, T.W. et al.
Downloaded from www.microbiologyresearch.org by
IP:  149.157.61.209
On: Fri, 23 Sep 2016 15:07:09
Molecular characterization of carbapenem-resistant
Acinetobacter species in an Irish university hospital:
predominance of Acinetobacter genomic species 3
T. W. Boo,1 F. Walsh1 and B. Crowley2
Correspondence
B. Crowley
bcrowley@stjames.ie
1Department of Clinical Microbiology, Trinity College, University of Dublin, James’s Street, Dublin 8,
Ireland
2Central Pathology Laboratory, Department of Microbiology, St James’s Hospital, James’s Street,
Dublin 8, Ireland
Received 10 July 2008
Accepted 9 October 2008
A 30 month prospective study of Acinetobacter species encountered in the Central Pathology
Laboratory of St James’s Hospital, Dublin, Ireland, was conducted to investigate the prevalence
and molecular epidemiology of carbapenem resistance in such isolates. Acinetobacter genomic
species 3 (AG3) was found to be the predominant Acinetobacter species (45/114, 39%) in our
institution. A total of 11% of all Acinetobacter species (12/114) and 22% of AG3 isolates (10/
45) were carbapenem resistant. Carbapenem resistance was mediated by Ambler class D b-
lactamase OXA-23 in all 12 isolates, with insertion sequence ISAba1 found upstream of blaOXA-
23. ISAba1 was also found upstream of blaADC-25, which encodes the enzyme AmpC, in an
Acinetobacter baumannii isolate, and upstream of the aminoglycoside-acetyltransferase-
encoding gene aacC2 in three AG3 isolates. Inter-species plasmidic transfer was most likely
involved in the emergence and spread of blaOXA-23 among the Acinetobacter isolates within our
institution. The emergence of carbapenem resistance was associated not only with prior
carbapenem use but also with the use of other antimicrobial agents, most notably b-lactam/b-
lactamase-inhibitor combinations. The study demonstrated the emerging trend of carbapenem
resistance in the wider context of the Acinetobacter genus, and reiterated the paramount
importance of the prudent use of antimicrobial agents, stringent infection control measures and
resistance surveillance of pathogens.
INTRODUCTION
Acinetobacter spp. have become major pathogens in
hospital-associated infections, especially in critical care
settings such as intensive care units (ICUs) and units for
patients with severe burns (Murray & Hospenthal, 2008;
Sunenshine et al., 2007). They can survive in the hospital
environment for long periods and have a remarkable
propensity to develop resistance to multiple classes of
antimicrobial agents. As a result, they can cause a variety of
infections including ventilator-associated pneumonia and
bacteraemia. Carbapenems have been a particularly useful
group of antibiotics in the treatment of such infections as
they are b-lactams with the broadest spectra of activity.
They are clinically effective against Gram-negative organ-
isms producing Ambler classes A and C extended-spectrum
b-lactamases. However, carbapenem resistance in
Acinetobacter has been increasingly reported worldwide,
attributable mainly to Ambler class D carbapenemases and
class B metallo-b-lactamases (MBLs) (Poirel & Nordmann,
2006; Walther-Rasmussen & Høiby, 2006). This emerging
trend is of grave concern given the prospect of a further
reduction in therapeutic options for infections by these
multi-drug-resistant organisms. Following the emergence
of carbapenem-resistant Acinetobacter species in St James’s
Hospital in 2005 (Boo et al., 2006), a prospective study of
Acinetobacter isolates encountered in the Central Pathology
Laboratory, St James’s Hospital, was conducted to ascertain
the clinical epidemiology, molecular mechanisms and
genetic regulation of these carbapenem-resistant isolates.
Abbreviations: AG3, Acinetobacter genomic species 3; CLSI, Clinical
and Laboratory Standards Institute; ICU, intensive care unit; MBL,
metallo b-lactamase.
The GenBank/EMBL/DDBJ accession numbers for the Acinetobacter
sequences reported in this paper are as follows: EU827524
(Acinetobacter genomic species 3 ISAba1/blaOXA-23/ATPase),
EU827525 (Acinetobacter johnsonii ISAba1/blaOXA-23/ATPase),
EU827526 (Acinetobacter baumannii ISAba1/blaOXA-23/ATPase),
EU835512 (Acinetobacter baumannii ISAba1/blaADC-25), EU839488
(Acinetobacter genomic species 3 ISAba1/aacC2), EU872057
(Acinetobacter johnsonnii aacC2).
A table of primer sequences is available as supplementary material with
the online version of this paper.
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METHODS
Collection of Acinetobacter isolates. Isolates were prospectively
screened and collected in the Central Pathology Laboratory of St
James’s Hospital over a 30 month period from May 2005 to October
2007. In cases where there were two or more specimens yielding the
same organism in a patient, the first isolate from each patient episode
was chosen.
Identification of organisms. Acinetobacter isolates were presump-
tively identified using the Vitek-2 GNI identification system
(bioMe´rieux). Confirmatory identification and speciation was carried
out by PCR and sequencing of the rpoB gene and flanker regions, as
described by La Scola et al. (2006). In this study, a 500 bp segment of
the rpoB gene, as well as a region of variable size flanking the rpoB and
rpoC genes, were selected for PCR and sequencing.
Antimicrobial susceptibility testing. Antimicrobial susceptibility
testing was performed using Vitek GNI susceptibility test system
(bioMe´rieux) for the following antimicrobial agents: ampicillin,
amoxicillin–clavulanate, piperacillin–tazobactam, cefoxitin, cefotax-
ime, ceftazidime, cefepime, meropenem, ciprofloxacin, trimetho-
prim–sulphamethoxazole, gentamicin and amikacin. MICs were
determined using Etest strips (bioMe´rieux) for the above antimicro-
bial agents, as well as for the following agents: tigecycline, colistin and
imipenem. Carbapenem-resistant isolates were also screened pheno-
typically for the presence of MBL using imipenem versus
imipenem+EDTA Etest MIC strips (bioMe´rieux). Resistance was
defined using Clinical and Laboratory Standards Institute (CLSI)
breakpoints (CLSI, 2006).
Screening for carbapenem-resistance genes. PCR was per-
formed using primers for Ambler class B b-lactamase-encoding genes
blaVIM, blaIMP, blaSPM, blaGIM and blaSIM (Castanheira et al., 2004;
Lee et al., 2005; Pitout et al., 2005), as well as Ambler class D
carbapenemase-encoding genes blaOXA-23-like, blaOXA-24-like, blaOXA-51-like
and blaOXA-58 (Afzal-Shah et al., 2001; Coelho et al., 2006; He´ritier et al.,
2005) (Supplementary Table S1 available with the online journal). The
PCR was carried out in the GeneAmp 9700 PCR system thermal cycler
(Applied BioSystems) using a Qiagen PCR core kit (Qiagen) under the
conditions specified by the manufacturer.
Screening of other resistance genes. PCR was also performed to
screen for other resistance genes that might be present in
carbapenem-resistant isolates, including those encoding Ambler class
A b-lactamase-encoding genes (blaTEM, blaSHV, blaCTX-M, blaVEB and
blaPER) (Hopkins et al., 2006; Naas et al., 2006) and Ambler class C
Acinetobacter-derived cephalosporinase-encoding genes (blaADC)
(Hujer et al., 2005). The presence of integrons was screened using
primers specific for class 1 and class 2 integrases (Koeleman et al.,
2001). Aminoglycoside resistance was investigated by screening for
genes encoding aminoglycoside-modifying enzymes, aacC1, aacC2
and aphA6 (Vila et al., 1999). The primers are shown in
Supplementary Table S1 available with the online journal.
Screening for insertion sequence ISAba1. The presence of the
ISAba1 insertion sequence, upstream of the resistance genes and in
the correct orientation to promote resistance-gene expression, was
sought using a forward primer homologous to sequences located
within ISAba1 and reverse primers homologous to the respective
resistance genes.
Nucleotide sequencing. Sequencing of amplicons in both direc-
tions was performed at the Institute of Molecular Medicine, Trinity
College, University of Dublin, with the ABI Prism 3130xl analyser
(Applied BioSystems) using the BigDye terminator V3.1 cycle
sequencing kit (Applied BioSystems) according to the manufacturer’s
specifications. Sequences were aligned using CLUSTAL W software
(www.ebi.ac.uk/Tools/clustalw) and compared with existing GenBank
sequences using the BLAST programme (www.ncbi.nih.gov/blast). The
sequences of our isolates were submitted to GenBank, National
Center for Biotechnology Information (www.ncbi.nih.gov/Genbank).
Epidemiological typing of isolates. Epidemiological typing of
carbapenem-resistant isolates was carried out using PFGE following
digestion of genomic DNA by restriction endonuclease ApaI as
described by Seifert et al. (2005). The PFGE patterns were analysed
using BioNumerics software (BioSystematica) according to the
criteria described by Tenover et al. (1995).
Plasmid studies. Plasmid extraction of bacterial suspensions was
carried out using a plasmid midi kit (Qiagen) according to the
manufacturer’s specifications. PCR using the plasmid preparations as
templates was performed to ascertain whether the carbapenem-
resistance genes were plasmid borne. PCR of the rpoB gene was also
performed using the same plasmid preparations to look for evidence
of chromosomal contamination during the extraction procedure.
Following gel electrophoresis, DNA from individual plasmid bands
was eluted using a gel extraction kit (Qiagen) and used as template for
PCR to ascertain the sizes of the plasmids carrying the resistance
genes.
Clinical and epidemiological data for the patients. Clinical,
epidemiological and demographic data for the patients were obtained
from clinical case notes and from the Central Pathology Laboratory
surveillance database. Infection was defined as the isolation of the
organism from a normally sterile site; or clinical evidence of sepsis
originating from a normally non-sterile site where significant colony
counts of the organism had been cultured.
RESULTS AND DISCUSSION
Species identification of Acinetobacter isolates
A total of 114 Acinetobacter isolates were collected in the
Central Pathology Laboratory over the stipulated period.
The Vitek-2 GNI identification system identified the
isolates (and their numbers) as follow: Acinetobacter
baumannii (77), Acinetobacter lwoffii (31), Acinetobacter
junii (2), Acinetobacter haemolyticus (4). However, rpoB
gene sequencing revealed the distribution of the various
species as shown in Table 1. All amplicons had sequence
concordance of 98 to 100% when compared with the
respective reference GenBank sequences (La Scola et al.,
2006). A total of 39% (45/114) of all isolates were
Acinetobacter genomic species 3 (AG3) while A. baumannii
constituted 22% (25/114) of the total. The predominance
of AG3 over A. baumannii was an unusual finding but such
an epidemiology had occasionally been reported in
hospitals (Traub & Bauer, 2000). This study also demon-
strated the poor accuracy of the speciation of Acinetobacter
species by the Vitek-2 GNI identification system, with 75%
of isolates erroneously speciated. It highlights the need to
regard such results as preliminary data. Accurate speciation
using molecular methods not only is important in the
investigation of outbreaks caused by Acinetobacter species,
but also is relevant in epidemiological studies such as this
report.
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Antimicrobial susceptibility of carbapenem-
resistant isolates
Vitek-2 MICs corresponded closely with those obtained
with the Etest method. Of the 114 isolates, 12 (11% of the
total) were resistant to both meropenem and imipenem
(MICs of ¢32 mg l21) (Table 1). Ten isolates were AG3,
while the remaining two were A. baumannii and
Acinetobacter johnsonii. The remaining 102 isolates were
susceptible to both meropenem and imipenem (MICs of
¡4 mg l21). A significant proportion (22%) of the AG3
isolates was thus found to be carbapenem resistant, and to
the authors’ knowledge, this study is the first report of a
carbapenem-resistant A. johnsonii clinical isolate.
Worldwide, the overwhelming majority of carbapenem-
resistant isolates are A. baumannii isolates. AG3 has rarely
been reported to be carbapenem resistant (Boo et al., 2006;
Marti et al., 2008b). The unusual predominance of AG3
among the carbapenem-resistant isolates in our institution
probably reflects the relative distribution of the various
Acinetobacter species locally. This study adds to the
emerging reports of carbapenem resistance in clinical
isolates of Acinetobacter species other than A. baumannii,
such as Acinetobacter genomic species 13TU and genomic
species 16 (Marti et al., 2008a; Martinovich et al., 2008).
Since species such as AG3 and 13TU were also associated
with clinically important infections (Traub & Bauer, 2000),
the development of carbapenem resistance in these species
is yet another worrisome development in multidrug
resistance within the Acinetobacter genus.
The antimicrobial susceptibility results of the 12 isolates
can be divided into 4 antibiograms (Table 2). All 12 isolates
demonstrated full resistance to ampicillin, amoxicillin–
clavulanate, piperacillin–tazobactam, cefoxitin, merope-
nem, imipenem and ciprofloxacin., while all isolates had
colistin MICs of¡0.5 mg l21. Ratios of¢8 with the MBL
Etest (imipenem MIC versus imipenem+EDTA MIC)
were obtained for the 12 isolates, giving presumptive
positive results for MBL. Seven AG3 isolates (antibiogram
1) were susceptible to ceftazidime, aminoglycosides and
trimethoprim–sulphamethoxazole, and had intermediate
or full resistance to cefotaxime and cefepime. Antibiogram
2 (A. johnsonii) had a similar profile as antibiogram 3
(three remaining AG3 isolates) but with lower cephalos-
porin MICs and a higher gentamicin MIC. Of note, all AG3
and A. johnsonii isolates had cefepime MICs that were two
to eight times higher than those of ceftazidime. The A.
baumannii isolate was highly resistant to cephalosporins,
trimethoprim–sulphamethoxazole and aminoglycosides
(antibiogram 4). All AG3 and A. johnsonii isolates had
tigecycline MICs of ¡0.5 mg l21, while the A. baumannii
isolate had a tigecycline MIC of 2 mg l21.
Carbapenem-resistance genes and their genetic
surroundings
The resistance genes of the various isolates are summarized
in Table 3. PCR was negative for blaVIM, blaIMP, blaSPM,
blaGIM, blaSIM, blaOXA-24-like and blaOXA-58. False-positive
results were thus obtained with the MBL Etest, which
serves as a reminder that PCR confirmation of such results
is still required as OXA carbapenemases can produce false-
positive MBL results (Segal & Elisha, 2005). To date, there
is still no reliable phenotypic method distinguishing MBLs
from OXA carbapenemases.
Table 1. Speciation and meropenem MICs of Acinetobacter isolates collected in the Central Pathology Laboratory, St James’s
Hospital (May 2005 to October 2007)
Acinetobacter species No. of isolates Meropenem and imipenem
MICs of ¢32 mg l”1*
(percentage within species)
Meropenem and imipenem
MICs of ¡4 mg l”1*
(percentage within species)
All species 114 12 (11%) 102 (89%)
Acinetobacter genomic species 3 45 10 (22%) 35 (78%)
Acinetobacter baumannii 25 1 (4%) 24 (96%)
Acinetobacter calcoaceticus 5 0 5 (100%)
Acinetobacter genomic species 13 2 0 2 (100%)
Acinetobacter johnsonii 12 1 (8%) 11 (92%)
Acinetobacter ursingii 8 0 8 (100%)
Acinetobacter genomic species 9 5 0 5 (100%)
Acinetobacter lwoffii 2 0 2 (100%)
Acinetobacter genomic species 10 1 0 1 (100%)
Acinetobacter genomic species 11 4 0 4 (100%)
Acinetobacter haemolyticus 1 0 1 (100%)
Acinetobacter schindleri 1 0 1 (100%)
Acinetobacter tjernbergiae 1 0 1 (100%)
Acinetobacter radioresistens 2 0 2 (100%)
*Based on the Etest method; no isolate had an MIC of 8 or 16 mg l21.
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A. baumannii was positive for both blaOXA-23-like and
blaOXA-51-like genes, while the other 11 isolates were positive
for the blaOXA-23-like gene only. Nucleotide sequencing of
the blaOXA-23-like amplicons revealed that all 12 isolates
carried the classical blaOXA-23 gene, which has also been
reported in various continents including Europe, Asia and
America (Coelho et al., 2006; Corvec et al., 2007; Meric
et al., 2008; Valenzuela et al., 2007; Villegas et al., 2007;
Zong et al., 2008). In addition, the insertion sequence
ISAba1 was found immediately upstream of blaOXA-23 in all
12 isolates (separated by 17 nucleotides); while the ATPase-
encoding gene was found downstream of it. The regions
between ISAba1 and blaOXA-23 of all 12 isolates were
identical in sequence, as were the regions between blaOXA-23
and ATPase-encoding gene (104 nucleotides in length).
ISAba1 was not present upstream of the blaOXA-51-like gene
in the A. baumannii isolate. Hence the b-lactamase-
encoding gene contributing to carbapenem resistance for
all 12 isolates from St James’s Hospital was blaOXA-23, since
ISAba1 was shown to possess promoter sequences that
upregulated expression of the b-lactamase-encoding genes
downstream (Corvec et al., 2007; He´ritier et al., 2006).
Additional mechanisms of resistance that have not been
investigated in this study, such as loss of membrane porins
and multidrug efflux pump, may also play important roles
in the development of carbapenem resistance (Dupont
et al., 2005; Magnet et al., 2001; Siroy et al., 2005).
Other resistance genes
No Ambler class A b-lactamase-encoding genes (blaTEM,
blaSHV, blaCTX-M, blaVEB and blaPER) were detected by PCR.
The Ambler class C ADC-encoding genes of the AG3 and
A. baumannii isolates were sequenced. All 10 AG3 isolates
were positive for blaADC-18 (.99% concordance with
GenBank accession number AM283523), while the A.
Table 2. Antimicrobial susceptibility patterns of the carbapenem-resistant isolates
Susceptibility was determined according to CLSI interpretation criteria (CLSI, 2006). I, intermediate; R, Resistant; S, susceptible.
Antimicrobial agent Antibiogram 1
(MIC value)
Antibiogram 2
(MIC value)
Antibiogram 3
(MIC value)
Antibiogram 4
(MIC value)
Cefotaxime I/R (32–64 mg l21) I (16 mg l21) R (128–¢256 mg l21) R (¢256 mg l21)
Ceftazidime S (4–8 mg l21) S (8 mg l21) I/R (16–32 mg l21) R (¢256 mg l21)
Cefepime I/R (16–64 mg l21) R (32 mg l21) R (64–128 mg l21) R (¢256 mg l21)
Trimethoprim–sulfamethoxazole S (¡1/19 mg l21) R (¢32/608 mg l21) R (¢32/608 mg l21) R (¢32/608 mg l21)
Gentamicin S (0.25–1 mg l21) R (128 mg l21) R (32 mg l21) R (¢256 mg l21)
Amikacin S (0.5–2 mg l21) S (1 mg l21) S (0.5–2 mg l21) R (¢256 mg l21)
Types of isolates (no.) AG3 (7) A. johnsonii (1) AG3 (3) A. baumannii (1)
Isolate identifier S659, A629, S448, S748,
S165, A594, A616
A868 A540, A277, A357 U437
Table 3. Resistance genes of carbapenem-resistant isolates
Isolate identifier Species Resistance gene/cassette encoding:
OXA ADC Aminoglycoside-modifying
enzymes
Class 1 integron
A540 AG3 ISAba1+OXA-23 ADC-18 ISAba1+aacC2 2
S659 AG3 ISAba1+OXA-23 ADC-18 2 2
A629 AG3 ISAba1+OXA-23 ADC-18 2 2
S448 AG3 ISAba1+OXA-23 ADC-18 2 2
S748 AG3 ISAba1+OXA-23 ADC-18 2 2
A594 AG3 ISAba1+OXA-23 ADC-18 2 2
A616 AG3 ISAba1+OXA-23 ADC-18 2 2
A277 AG3 ISAba1+OXA-23 ADC-18 ISAba1+aacC2 2
A357 AG3 ISAba1+OXA-23 ADC-18 ISAba1+aacC2 2
S165 AG3 ISAba1+OXA-23 ADC-18 2 2
U437 A. baumannii OXA-51 group;
ISAba1+OXA-23
ISAba1+ADC-25 aphA6 +
A868 A. johnsonii ISAba1+OXA-23 ?* aacC2 2
+, Present; 2, absent
*PCR product not obtained with study primers.
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baumannii isolate was positive for blaADC-25 (.99%
concordance with GenBank accession number EF016355).
We were unable to obtain an amplicon for the A. johnsonii
isolate with the blaADC primers used in this study. Since
OXA-23 has little activity on third and fourth generation
cephalosporins, the ADC enzymes are responsible for
hydrolysing these b-lactams. The cephalosporin suscept-
ibility profiles (where cefepime MICs were higher than
ceftazidime MICs) of the AG3 isolates were different from
those of most Ambler class C enzymes of other Gram-
negative organisms as well as some ADC enzymes such as
ADC-7 (Hujer et al., 2005). This suggests that different
ADC subtypes may have different affinities for the various
cephalosporins. ISAba1 was found upstream of the A.
baumannii blaADC-25, but not of the blaADC-18 of the AG3
isolates.
The A. baumannii isolate was the only isolate to possess a
class 1 integron and also carried the aminoglycoside
phosphotransferase-encoding gene aphA6 (99% concord-
ance with GenBank accession number X07753), which
accounted for the resistance to amikacin as well as
gentamicin. The three gentamicin-resistant AG3 isolates
were positive for the aminoglycoside-acetyltransferase-
encoding gene aacC2 (100% concordance with GenBank
accession number AY138987). ISAba1 was found upstream
of the aacC2 gene in all three isolates, with a truncated 39
end of insertion sequence IS1133 found between ISAba1
and aacC2 (GenBank accession number EU839488). The
aacC2 gene was also found in the A. johnsonii isolate, but
without ISAba1 upstream of it. This study demonstrates
the role of ISAba1 in the regulation of various b-lactamase-
encoding genes in A. baumannii and also in other
Acinetobacter species. Not only was it found upstream of
the blaOXA-23 of various species, but was also found
upstream of the blaADC-25 gene in A. baumannii.
Upregulation of blaADC-25 was the most likely explanation
for the higher cephalosporin MICs of A. baumannii in
contrast to those of the AG3 isolates, which did not possess
ISAba1 upstream of blaADC-18. The role of ISAba1 in the
regulation of genes encoding aminoglycoside-modifying
enzymes was less clear. Gentamicin MICs of AG3 isolates
possessing ISAba1 upstream of aacC2 were lower than
MICs observed in A. baumannii and A. johnsonii where
ISAba1 was absent upstream of aphA6 and aacC2,
respectively. This would suggest that ISAba1 did not
upregulate the expression of such genes. Other mechanisms
of resistance may also have contributed to aminoglycoside
resistance in our isolates. In particular, overexpression of
multidrug efflux pumps such as AdeABC confers resistance
to aminoglycosides and several other classes of antimicro-
bial agents in A. baumannii (Magnet et al., 2001).
Epidemiological typing and plasmid studies
The ten AG3 isolates were divided into two genotype
groups according to their PFGE banding patterns. Group
1 contained seven isolates S659, A629, A616, A594, S448,
S748 and S165 that had ¢85% similarity and therefore
were closely related. Within this group isolates S448 and
S748 were clonally related with identical PFGE patterns. In
group 2, isolates A540, A277 and A357 had indistinguish-
able PFGE patterns and hence were clonal. The two
groups had ,70% similarity to each other and therefore
were not related. PFGE groups 1 and 2 corresponded
closely with antibiogram patterns 1 and 3, respectively
(Table 2).
Four isolates [A. baumannii (U437), A. johnsonii (A868),
and representative AG3 isolates of the two PFGE clusters
([A357 and S448)] were used for the plasmid studies. PCRs
of plasmid preparations for all four isolates were positive
for blaOXA-23, while the PCR for the rpoB gene was
negative for all four isolates. This indicated that the
plasmid preparations were free of chromosomal contam-
ination and that blaOXA-23 was plasmid borne for the four
isolates. Following gel electrophoresis of the plasmid
preparations, A. johnsonii and AG3 (isolate A357)
demonstrated two plasmid bands of about 40 MDa and
about 95 MDa. No bands could be visualized for A.
baumannii and the other AG3 isolate (S448), which might
be the result of lower copy numbers within the prepara-
tions. The plasmid bands from the former two isolates
were eluted and PCR was positive for blaOXA-23 for the 40
MDa bands in both isolates, implying that blaOXA-23 was
carried on the 40 MDa plasmids in these isolates. Thus,
while PFGE demonstrated the two different clones and
closely related isolates of carbapenem-resistant AG3,
plasmid studies also revealed that plasmidic transfer of
blaOXA-23 between different Acinetobacter species (at least
between AG3 and A. johnsonii) most probably occurred in
our institution as well. This is further supported by the
similarities of the genetic surroundings of blaOXA-23
among the different species. This presents a worrying
prospect that multiple mechanisms, such as inter-species
plasmidic transfer and to a lesser degree, clonal spread, are
likely to be involved in promoting the spread of
carbapenem resistance within the Acinetobacter population
in our hospital.
Clinical and epidemiological data
The microbiological data of the isolates, and the clinical
and demographic data of the respective patients are
summarized in Table 4. Carbapenem-resistant Acinet-
obacter were isolated from a variety of specimens including
sputum, urine, swabs and third-space fluids. There was a
male-to-female patient ratio of 2 : 1 and most were hospital
in-patients for longer than 2 weeks when culture-positive.
The majority of the patients were infected with the
organisms and most had significant co-morbidities and/
or major surgery. Epidemiologically, the patients were
located in a wide variety of settings, not just the critical-
care settings. Most notably, the A. baumannii isolate was
isolated from a patient from the community, although it
was unclear whether there was a history of prior
Carbapenem-resistant Acinetobacter in an Irish hospital
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Table 4. Clinical data for patients with carbapenem-resistant Acinetobacter isolates
Isolate Specimen data Patient data
Organism Date of
isolation
(month/
year)
Specimen
type
Age
(years)
Sex Location Duration
of stay in
hospital*
Infection
status of
organism
Recent anti-Gram-
negative antibiotics
Underlying condition
S659 AG3 05/05 Sputum 49 M ICU 19 days Colonized Mer, Cip Crohn’s disease; pancolectomy
A540 AG3 08/05 Biliary fluid 62 F Surgical ward A 37 days Infected Ptz, Cip Pancreatic carcinoma; gastrojejunostomy
A629 AG3 03/06 Biliary fluid 71 F Surgical ward B 15 days Infected Aug, Cip Pancreatic carcinoma; biliary tract surgery
A868 A. johnsonii 05/06 Chest drain fluid 44 M Medical ward A 61 days Infected Cip Liver failure, recurrent empyema
A616 AG3 06/06 Wound swab 44 M ICU 29 days Infected Ptz, Cip Severe trauma, rhabdomyolysis, viral hepatitis
A594 AG3 07/06 Leg wound 49 M Surgical ward C 22 days Colonized Pen, Clox Lower limb cellulitis
S448 AG3 08/06 Sputum 56 F Oncology ward 58 days Infected Mer, Cip Oesophageal carcinoma, diabetes mellitus
S748 AG3 09/06 Sputum 73 M Oncology ward 5 daysD Colonized Aug, Cip Lung carcinoma
A357 AG3 10/06 Leg swab 62 M ICU 24 days Colonized Ptz, Cip Abdominal surgery, cardiovascular disease
A277 AG3 12/06 Leg swab 57 M Surgical ward D 33 days Colonized Cip Major trauma and surgery
S165 AG3 05/07 Sputum 64 M Medical ward B 27 days Infected Ptz, Cip Wegener’s granulomatosus, diabetes mellitus
U437 A. baumannii 08/07 Urine 71 F Community NA Infected Data unavailable Data unavailable
Aug, Amoxicillin–clavulanate; Cip, ciprofloxacin; Mer, meropenem; NA, not applicable; Pen, penicillin; Ptz, piperacillin–tazobactam.
*Duration from time of admission to the time of organism isolation in the current patient episode.
DTransferred from another hospital.
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hospitalization in the patient. However, there was also
some degree of clonal persistence within the institution.
AG3 isolates S448 and S748 were isolated in the oncology
ward a month apart; while A357 and A277 were isolated 2
months apart in the ICU and surgical ward, respectively,
although the patient with isolate A277 had been in the ICU
prior to transfer to the surgical ward (ward transfer data
are not included in Table 4). Nonetheless, the sporadic
nature and different settings for most of the isolates that
emerged, together with the findings that different species
and clones were involved, would suggest that there was a
reservoir of carbapenem-resistant Acinetobacter isolates
within the patient population served by the hospital.
These organisms might then have manifested following
antimicrobial therapy.
Of the 11 patients for whom there were data on
antimicrobial therapy prior to the isolation of the
organisms, only 2 had prior meropenem treatment. Six
had prior therapy with b-lactam/b-lactamase-inhibitor
combinations. This raises the possibility of co-selection of
carbapenem-resistant isolates by these antimicrobial agents
through the acquisition of OXA carbapenemases, since
these enzymes possess greater activity against these agents
(as well as the carbapenems) than the Ambler class C
Acinetobacter-derived cephalosporinases. As ten patients
had prior therapy with ciprofloxacin, it may also have a
role in selecting out quinolone-resistant isolates concomi-
tantly carrying the OXA-carbapenemase-encoding genes or
isolates overexpressing multidrug efflux pumps with
resistance to multiple classes of antimicrobial agents.
These observations emphasize the importance of the
prudent use of all antimicrobial agents, as non-carbapenem
agents may have a role in promoting the emergence of
carbapenem-resistant Acinetobacter isolates.
There are now mounting data to suggest that the presence
of Acinetobacter can contribute adversely to the prognosis
of patients, especially in the presence of significant co-
morbidities (Grupper et al., 2007; Murray & Hospenthal,
2008), and multidrug resistance in such isolates is
associated with increased mortality and prolonged hospit-
alization (Lee et al., 2007; Sunenshine et al., 2007).
Furthermore, since carbapenems are frequently used for
the treatment of such multidrug-resistant Acinetobacter
infections, carbapenem resistance can further contribute to
mortality as a result of discordant empirical therapy (Kwon
et al., 2007). In view of such findings, there is now an even
greater urgency for resistance surveillance of such organ-
isms as well as the prudent use of antimicrobial agents.
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